Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials
- 30 March 2025
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 237, 106154
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82230076, 82221004)
- Tsinghua University
- University of Tokyo (DSP8-11, DSP1-7)
- Chinese Academy of Meteorological Sciences (2022-I2M-1-021)
This publication has 36 references indexed in Scilit:
- Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variantsCell Reports, 2024
- Development of SARS-CoV-2 entry antiviralsCell Insight, 2024
- A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal deliveryScience China Life Sciences, 2023
- Potent antibodies against immune invasive SARS-CoV-2 Omicron subvariantsInternational Journal of Biological Macromolecules, 2023
- The Effects of Remdesivir and Dexamethasone on Renal Sirtuin-1 Expression and Renal Function in Male RatsApplied Biochemistry and Biotechnology, 2023
- Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineagesiScience, 2023
- Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptidesAntiviral Research, 2023
- Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptidesAntiviral Research, 2022
- Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case–noncase studyKidney International, 2021
- ACE2: The Major Cell Entry Receptor for SARS-CoV-2Lung, 2020